US pharmacy pricing
Rezdiffra Prices at US Pharmacies
Lowest price found · US pharmacies
$4,148.12/fill
for Rezdiffra, across the pharmacies in our data
US pharmacy prices — 100mg
| Pharmacy | Discount-card price | Regular cash price | Average retail |
|---|---|---|---|
| $4,148.12Lowest | $4,151.12 | $123.48 | |
| $4,148.12Lowest | $4,151.12 | $123.48 | |
| $4,332.17 | $4,332.17 | $123.48 | |
| $4,353.36 | $4,356.36 | $123.48 | |
| $4,380.04 | $4,383.04 | $123.48 | |
| $4,453.86 | $4,456.86 | $123.48 | |
| $4,453.86 | $4,456.86 | $123.48 | |
| $4,478.79 | $4,481.79 | $123.48 |
"Discount-card price" reflects a standard prescription discount card, not insurance. Prices change often — confirm at the pharmacy before filling.
Interchangeable forms
Per RxNorm (U.S. National Library of Medicine), these share the same active ingredient and strength as Rezdiffra.
Frequently asked questions
How much does Rezdiffra (Rezdiffra) cost without insurance?
At the US pharmacies in our data, the lowest listed discount-card price for Rezdiffra is around $4,148.12. Prices vary by pharmacy, dosage, and pack size, so use the table above to compare specific options near you.
Is a generic version of Rezdiffra available?
Generic and brand-name pricing for Rezdiffra is broken out in the tables above where both exist in our data. Generic versions are typically the lower-cost option, but availability depends on the specific formulation and dosage.
How is the price of Rezdiffra determined with insurance coverage?
Your out-of-pocket cost for Rezdiffra with insurance depends on several factors, including your specific plan's coverage, the drug's tier on the formulary, and whether your annual deductible has been met. For the most accurate and current pricing, contact your insurance provider directly.
Is a generic version of Rezdiffra available?
No. Rezdiffra received its initial FDA approval in March 2024 and is currently only available as a brand-name medication. A generic version is not expected to be on the market for several years.
What is Rezdiffra and what condition does it treat?
Rezdiffra is an FDA-approved prescription medication for adults with noncirrhotic nonalcoholic steatohepatitis (NASH) accompanied by moderate to advanced liver fibrosis (scarring). It is used alongside diet and exercise. NASH is a serious form of non-alcoholic fatty liver disease characterized by liver fat accumulation, inflammation, and damage that can progress to scarring, unrelated to alcohol consumption. The drug's active ingredient, resmetirom, is a thyroid hormone receptor-beta agonist. It received accelerated approval, meaning continued authorization for this use depends on verifying clinical benefit in ongoing confirmatory trials. Rezdiffra is not approved for treating cirrhosis or for use in patients under 18.